UBS maintains Neutral rating on Imeik and lowers target price from Rmb164 to Rmb123
AI summary card
UBS maintains Neutral rating on Imeik and lowers target price from Rmb164 to Rmb123
The report believes Imeik's earnings may have bottomed in 2025, and revenue is expected to resume growth in 2026 driven by new products such as AestheFill, botulinum toxin, and radiofrequency devices, but product mix changes and intensifying competition will continue to pressure margins.
- 2025 sales fell 19% year-on-year, and net profit fell 34% year-on-year, mainly due to declines in mature products, pressure on average selling prices, and the lower profitability of Regen Biotech.
- UBS expects revenue to return to growth in 2026, with new products expected to contribute Rmb700m in sales and drive a 15% CAGR in sales from 2026 to 2028.
- Due to declining ASPs for mature products, lower margins on new products, and increased promotional expenses, UBS expects net margin to contract by 8 percentage points from 2025 to 2028.
- UBS cut its 2026-2028 earnings forecasts by 11%-15% and lowered its DCF target price from Rmb164 to Rmb123, but maintained its Neutral rating as the stock has already corrected by more than 30% since the start of 2025.
Report interpretation
Overview
UBS published an earnings review on Imeik Technology Development, with the core view that the company's 2025 revenue and earnings performance was disappointing, but earnings may already have bottomed out. The report expects new products such as AestheFill, PowerFill, Type A botulinum toxin injection, and radiofrequency treatment devices to contribute incremental revenue starting in 2026, partially offsetting sales declines in mature products caused by intensifying competition. However, margins will remain under pressure because new products have lower margins than mature products, compounded by ASP pressure on mature products and rising selling and marketing expenses.
Core views
UBS believes Imeik's revenue will most likely return to growth in 2026, driven by resilient demand for high-end medical aesthetic services, the expansion of AestheFill in China and overseas following the consolidation of Regen Biotech, ramp-up of new capacity, and the potential launch of botulinum toxin and radiofrequency devices after approval. However, improvement in profitability is uncertain, as price competition in mature products, lower margins from new products, and higher spending will weigh on net margin. Considering the sharp stock price correction, valuation below historical averages, and expectations for earnings recovery, UBS believes the current risk-reward is balanced.
Analysis framework
The report uses company earnings review, channel checks, analysis of product pipeline and new product launch timing, earnings forecast revisions, DCF valuation, and peer and historical valuation comparisons. UBS lowered its 2026-2028 earnings forecasts by 11%-15%, mainly reflecting reduced assumptions for new-product profitability and higher expense ratios.
Methodology notes
Discounted cash flow target price
UBS sets a target price for Imeik based on DCF, lowering the target price from Rmb164 to Rmb123; WACC was reduced from 7.3% to 6.9% due to a lower beta.
Price-to-earnings valuation
The report notes that Imeik trades at 25x/24x 2026E/2027E P/E, which is 0.7 standard deviations below its historical average and broadly in line with China beauty and wellness peers.
Scenarios for key value drivers
The report uses injectable products, lyophilized powder sales, botulinum toxin sales, and net margin as value drivers, and assigns upside, base, and downside target prices of Rmb153, Rmb123, and Rmb83, respectively.
Asset mapping & comparison
Structured mapping from thesis to named assets (strengths, weaknesses, peers, risks).
- Imeik Technology Development (300896.SZ)Covered company
- Strengths
- A leading company in the medical aesthetics field, with an established sales network, and products adopted by more than 4,400 medical institutions; new products such as AestheFill, botulinum toxin, and radiofrequency devices provide growth drivers for 2026.
- Weaknesses
- Mature products face intensifying competition and declining ASPs, while Regen Biotech and new products have lower margins than mature products, and promoting new products may increase selling and marketing expenses.
- Comparison
- 2026E/2027E P/E is 25x/24x, 0.7 standard deviations below its historical average, and broadly in line with China beauty and wellness peers.
- Risks
- New product sales miss expectations, intensified competition in the medical aesthetic injectable market, tighter regulation, loss of R&D personnel, or insufficient response to technological iteration.
- Regen Biotech / AestheFillGrowth-driving subsidiary business and product
- Strengths
- AestheFill began contributing sales in China around September 2025, and is bringing incremental revenue through indication variants, domestic and international expansion, and ramp-up of new capacity.
- Weaknesses
- Profitability may be lower than Imeik's mature products, and product mix changes will reduce overall margins.
- Comparison
- Compared with mature products, AestheFill represents a source of new-product growth but with lower margins.
- Risks
- New product ramp-up is slower than expected, or capacity ramp-up or market promotion falls short of expectations.
- Type A botulinum toxin injection and radiofrequency treatment devicesPotential new product lines
- Strengths
- The botulinum toxin product was approved in January 2026, and the radiofrequency treatment device was approved in March 2026. UBS expects subsequent launches to help offset declines in mature products.
- Weaknesses
- Profitability may be low in the early stage after launch and may require higher promotional spending.
- Comparison
- Compared with mature injectable products, the new products have higher growth potential but lower margin and commercialization certainty.
- Risks
- There is uncertainty around launch timing, registration approval, sales ramp-up, and market competition.
Key data
- 12-month ratingNeutralUBS maintains a Neutral rating.
- Target priceRmb123.00DCF target price lowered from Rmb164.00.
- Current priceRmb116.42As of April 28, 2026.
- 2025 revenue changeYoY -19%Mainly due to nearly 30% decline in mature product sales, partially offset by consolidation of Regen Biotech.
- 2025 net profit changeYoY -34%Affected by ASP pressure on mature products and the lower profitability of Regen Biotech.
- 2026 forecast new product sales contributionRmb700mIncluding AestheFill, botulinum toxin, and radiofrequency energy devices.
- 2026-2028 forecast sales CAGR15%Driven by contributions from new products.
- 2026-2028 forecast EPS CAGR8%Revenue returning to growth drives profit recovery from the trough.
- 2026E EPS forecast revisionRmb4.62, down 15% from previous forecastPrevious forecast was Rmb5.41.
- 2027E EPS forecast revisionRmb4.94, down 14% from previous forecastPrevious forecast was Rmb5.71.
- 2028E EPS forecast revisionRmb5.37, down 11% from previous forecastPrevious forecast was Rmb6.02.
- 2026E/2027E P/E25x/24x0.7 standard deviations below historical average.
- Market capitalizationRmb35.2b / US$5.15bTrading data disclosed in the report.
Impact & implications
The implication of this report for Imeik is that the investment focus shifts from simply watching the 2025 earnings decline to judging whether new products can take over from mature products quickly enough and improve the growth trajectory. UBS does not dismiss the possibility of revenue recovery, but believes downward pressure on margins will weaken earnings elasticity, so even after a sharp stock price correction, the rating remains Neutral rather than turning positive.
Risks
- Intensifying competition in the medical aesthetic injectable market may lead to continued declines in sales and ASPs for mature products.
- Strict or tightening government regulation of the medical aesthetics industry may affect new product registration, qualification approvals, and overseas acquisitions.
- Technology R&D risks, including loss of key R&D personnel or failure to respond in time to technological advances.
- Sales of new products such as AestheFill, botulinum toxin, and radiofrequency devices may come in below expectations.
- New-product margins are lower than those of mature products, and combined with increased selling and marketing expenses, may lead to further margin decline.
What to watch
- Whether revenue in 2026 resumes growth as UBS expects, especially whether the sales decline continues to narrow after the first quarter.
- Sales expansion of AestheFill in China and overseas, launch of indication variants, and progress in ramping up capacity at the new factory.
- The official launch timing, sales ramp-up, and margin performance of Type A botulinum toxin injection and radiofrequency treatment devices.
- Changes in ASPs of mature products and the intensity of competition in the medical aesthetic injectable market.
- Whether selling expense ratio, R&D expense ratio, and net margin continue to face pressure as assumed by UBS.
- The valuation position of 2026E/2027E P/E relative to historical averages and China beauty and wellness peers.